Loading…
Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γ δ T Cells
Most vaccines are designed to attack tumor cells by activating CD4 + /CD8 + αβ T cells. Unfortunately, αβ T cells, which only recognize the peptide antigens in the complexes with polymorphic MHCI/II molecules, surrender to the tumor heterogenicity. As another subset of T cells, γδ T cells become sal...
Saved in:
| Published in: | Advanced functional materials 2023-10, Vol.33 (44) |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c847-6c27f801c2a63217674bff623fa236f07b7aa322e530c776b427c394b1b0299f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c847-6c27f801c2a63217674bff623fa236f07b7aa322e530c776b427c394b1b0299f3 |
| container_end_page | |
| container_issue | 44 |
| container_start_page | |
| container_title | Advanced functional materials |
| container_volume | 33 |
| creator | Yang, Zeyu Li, Liyan Wei, Chengxiu Liu, Hong Qiao, Dongdong Wen, Zhenfu Chen, Haolin Huang, Shanghui Guo, Rui Yin, Zhinan Liu, Lixin Chen, Yongming |
| description | Most vaccines are designed to attack tumor cells by activating CD4
+
/CD8
+
αβ
T cells. Unfortunately,
αβ
T cells, which only recognize the peptide antigens in the complexes with polymorphic MHCI/II molecules, surrender to the tumor heterogenicity. As another subset of T cells,
γδ
T cells become salient in antitumor because of their unique immunotherapeutic roles. Herein, a tumor vaccine is developed with multivalent antigens by fusion of tumor cell membranes with lipids and successfully activated
γδ
T cells via microneedle inoculation. It is certified that the evoked
γδ
T cells synchronize with
αβ
T cells revitalizing tumor‐induced immunotolerance. In turn, the tumors of mice are significantly inhibited and their median survival time is prolonged considerably. Moreover, the nanovaccine inhibits tumor recurrence after resection. The therapeutic effects are corroborated with the results from TCR
δ
−/−
mice as well as cytokine expression in tumor. |
| doi_str_mv | 10.1002/adfm.202303537 |
| format | article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1002_adfm_202303537</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1002_adfm_202303537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c847-6c27f801c2a63217674bff623fa236f07b7aa322e530c776b427c394b1b0299f3</originalsourceid><addsrcrecordid>eNo90E1OwzAUBGALgUQpbFn7AgnP76V2sqwifiqVH4ks2EWOsWlQEleJW5RzcBXO0TOhCNTVzGI0i4-xawGxAMAb_e7aGAEJaEHqhM2EFDIiwPT02MXbObsYhk8AoRQlM_b4pDu_18bUneWvG_9Vdx_8xQfbBb5q213nw8b2ejvy4Hmxa33Pq5EvTaj3Okzbwzc__PCC57Zphkt25nQz2Kv_nLPi7rbIH6L18_0qX64jkyYqkgaVS0EY1JJQKKmSyjmJ5DSSdKAqpTUh2gWBUUpWCSpDWVKJCjDLHM1Z_Hdrej8MvXXltq9b3Y-lgHKyKCeL8mhBv0FbUuo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γ δ T Cells</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Yang, Zeyu ; Li, Liyan ; Wei, Chengxiu ; Liu, Hong ; Qiao, Dongdong ; Wen, Zhenfu ; Chen, Haolin ; Huang, Shanghui ; Guo, Rui ; Yin, Zhinan ; Liu, Lixin ; Chen, Yongming</creator><creatorcontrib>Yang, Zeyu ; Li, Liyan ; Wei, Chengxiu ; Liu, Hong ; Qiao, Dongdong ; Wen, Zhenfu ; Chen, Haolin ; Huang, Shanghui ; Guo, Rui ; Yin, Zhinan ; Liu, Lixin ; Chen, Yongming</creatorcontrib><description>Most vaccines are designed to attack tumor cells by activating CD4
+
/CD8
+
αβ
T cells. Unfortunately,
αβ
T cells, which only recognize the peptide antigens in the complexes with polymorphic MHCI/II molecules, surrender to the tumor heterogenicity. As another subset of T cells,
γδ
T cells become salient in antitumor because of their unique immunotherapeutic roles. Herein, a tumor vaccine is developed with multivalent antigens by fusion of tumor cell membranes with lipids and successfully activated
γδ
T cells via microneedle inoculation. It is certified that the evoked
γδ
T cells synchronize with
αβ
T cells revitalizing tumor‐induced immunotolerance. In turn, the tumors of mice are significantly inhibited and their median survival time is prolonged considerably. Moreover, the nanovaccine inhibits tumor recurrence after resection. The therapeutic effects are corroborated with the results from TCR
δ
−/−
mice as well as cytokine expression in tumor.</description><identifier>ISSN: 1616-301X</identifier><identifier>EISSN: 1616-3028</identifier><identifier>DOI: 10.1002/adfm.202303537</identifier><language>eng</language><ispartof>Advanced functional materials, 2023-10, Vol.33 (44)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c847-6c27f801c2a63217674bff623fa236f07b7aa322e530c776b427c394b1b0299f3</citedby><cites>FETCH-LOGICAL-c847-6c27f801c2a63217674bff623fa236f07b7aa322e530c776b427c394b1b0299f3</cites><orcidid>0000-0003-2843-5543</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Yang, Zeyu</creatorcontrib><creatorcontrib>Li, Liyan</creatorcontrib><creatorcontrib>Wei, Chengxiu</creatorcontrib><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Qiao, Dongdong</creatorcontrib><creatorcontrib>Wen, Zhenfu</creatorcontrib><creatorcontrib>Chen, Haolin</creatorcontrib><creatorcontrib>Huang, Shanghui</creatorcontrib><creatorcontrib>Guo, Rui</creatorcontrib><creatorcontrib>Yin, Zhinan</creatorcontrib><creatorcontrib>Liu, Lixin</creatorcontrib><creatorcontrib>Chen, Yongming</creatorcontrib><title>Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γ δ T Cells</title><title>Advanced functional materials</title><description>Most vaccines are designed to attack tumor cells by activating CD4
+
/CD8
+
αβ
T cells. Unfortunately,
αβ
T cells, which only recognize the peptide antigens in the complexes with polymorphic MHCI/II molecules, surrender to the tumor heterogenicity. As another subset of T cells,
γδ
T cells become salient in antitumor because of their unique immunotherapeutic roles. Herein, a tumor vaccine is developed with multivalent antigens by fusion of tumor cell membranes with lipids and successfully activated
γδ
T cells via microneedle inoculation. It is certified that the evoked
γδ
T cells synchronize with
αβ
T cells revitalizing tumor‐induced immunotolerance. In turn, the tumors of mice are significantly inhibited and their median survival time is prolonged considerably. Moreover, the nanovaccine inhibits tumor recurrence after resection. The therapeutic effects are corroborated with the results from TCR
δ
−/−
mice as well as cytokine expression in tumor.</description><issn>1616-301X</issn><issn>1616-3028</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo90E1OwzAUBGALgUQpbFn7AgnP76V2sqwifiqVH4ks2EWOsWlQEleJW5RzcBXO0TOhCNTVzGI0i4-xawGxAMAb_e7aGAEJaEHqhM2EFDIiwPT02MXbObsYhk8AoRQlM_b4pDu_18bUneWvG_9Vdx_8xQfbBb5q213nw8b2ejvy4Hmxa33Pq5EvTaj3Okzbwzc__PCC57Zphkt25nQz2Kv_nLPi7rbIH6L18_0qX64jkyYqkgaVS0EY1JJQKKmSyjmJ5DSSdKAqpTUh2gWBUUpWCSpDWVKJCjDLHM1Z_Hdrej8MvXXltq9b3Y-lgHKyKCeL8mhBv0FbUuo</recordid><startdate>202310</startdate><enddate>202310</enddate><creator>Yang, Zeyu</creator><creator>Li, Liyan</creator><creator>Wei, Chengxiu</creator><creator>Liu, Hong</creator><creator>Qiao, Dongdong</creator><creator>Wen, Zhenfu</creator><creator>Chen, Haolin</creator><creator>Huang, Shanghui</creator><creator>Guo, Rui</creator><creator>Yin, Zhinan</creator><creator>Liu, Lixin</creator><creator>Chen, Yongming</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-2843-5543</orcidid></search><sort><creationdate>202310</creationdate><title>Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γ δ T Cells</title><author>Yang, Zeyu ; Li, Liyan ; Wei, Chengxiu ; Liu, Hong ; Qiao, Dongdong ; Wen, Zhenfu ; Chen, Haolin ; Huang, Shanghui ; Guo, Rui ; Yin, Zhinan ; Liu, Lixin ; Chen, Yongming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c847-6c27f801c2a63217674bff623fa236f07b7aa322e530c776b427c394b1b0299f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Zeyu</creatorcontrib><creatorcontrib>Li, Liyan</creatorcontrib><creatorcontrib>Wei, Chengxiu</creatorcontrib><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Qiao, Dongdong</creatorcontrib><creatorcontrib>Wen, Zhenfu</creatorcontrib><creatorcontrib>Chen, Haolin</creatorcontrib><creatorcontrib>Huang, Shanghui</creatorcontrib><creatorcontrib>Guo, Rui</creatorcontrib><creatorcontrib>Yin, Zhinan</creatorcontrib><creatorcontrib>Liu, Lixin</creatorcontrib><creatorcontrib>Chen, Yongming</creatorcontrib><collection>CrossRef</collection><jtitle>Advanced functional materials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Zeyu</au><au>Li, Liyan</au><au>Wei, Chengxiu</au><au>Liu, Hong</au><au>Qiao, Dongdong</au><au>Wen, Zhenfu</au><au>Chen, Haolin</au><au>Huang, Shanghui</au><au>Guo, Rui</au><au>Yin, Zhinan</au><au>Liu, Lixin</au><au>Chen, Yongming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γ δ T Cells</atitle><jtitle>Advanced functional materials</jtitle><date>2023-10</date><risdate>2023</risdate><volume>33</volume><issue>44</issue><issn>1616-301X</issn><eissn>1616-3028</eissn><abstract>Most vaccines are designed to attack tumor cells by activating CD4
+
/CD8
+
αβ
T cells. Unfortunately,
αβ
T cells, which only recognize the peptide antigens in the complexes with polymorphic MHCI/II molecules, surrender to the tumor heterogenicity. As another subset of T cells,
γδ
T cells become salient in antitumor because of their unique immunotherapeutic roles. Herein, a tumor vaccine is developed with multivalent antigens by fusion of tumor cell membranes with lipids and successfully activated
γδ
T cells via microneedle inoculation. It is certified that the evoked
γδ
T cells synchronize with
αβ
T cells revitalizing tumor‐induced immunotolerance. In turn, the tumors of mice are significantly inhibited and their median survival time is prolonged considerably. Moreover, the nanovaccine inhibits tumor recurrence after resection. The therapeutic effects are corroborated with the results from TCR
δ
−/−
mice as well as cytokine expression in tumor.</abstract><doi>10.1002/adfm.202303537</doi><orcidid>https://orcid.org/0000-0003-2843-5543</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1616-301X |
| ispartof | Advanced functional materials, 2023-10, Vol.33 (44) |
| issn | 1616-301X 1616-3028 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_adfm_202303537 |
| source | Wiley-Blackwell Read & Publish Collection |
| title | Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γ δ T Cells |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A08%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanovaccine%20Showing%20Potent%20Immunotherapy%20to%20Tumor%20by%20Activating%20%CE%93%20%CE%B4%20T%20Cells&rft.jtitle=Advanced%20functional%20materials&rft.au=Yang,%20Zeyu&rft.date=2023-10&rft.volume=33&rft.issue=44&rft.issn=1616-301X&rft.eissn=1616-3028&rft_id=info:doi/10.1002/adfm.202303537&rft_dat=%3Ccrossref%3E10_1002_adfm_202303537%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c847-6c27f801c2a63217674bff623fa236f07b7aa322e530c776b427c394b1b0299f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |